SMW Free Realtime Trade Alerts -- Fast Moving Stocks < $15 -- Join Today for FREE!!

GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading GWPH News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
-0.72%26.097.5%$403.89m
SHPGShire PLC Sponsored ADR
-0.60%199.020.7%$205.07m
PRGOPerrigo Co. Plc
0.09%96.864.2%$182.70m
ENDPEndo International Plc
-1.47%22.206.2%$127.26m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.04%126.2110.1%$126.06m
MNKMallinckrodt Plc
0.31%71.454.7%$110.12m
AERIAerie Pharmaceuticals, Inc.
-3.88%39.1416.0%$92.96m
JAZZJazz Pharmaceuticals Plc
-0.69%125.023.3%$84.06m
ICPTIntercept Pharmaceuticals, Inc.
-2.81%167.3017.4%$67.51m
UTHRUnited Therapeutics Corporation
-4.24%116.8417.5%$64.74m
HZNPHorizon Pharma plc
-1.75%18.539.8%$56.81m
CTLTCatalent Inc
-0.80%26.163.8%$55.68m
RPTPRaptor Pharmaceutical Corp.
0.17%8.977.5%$42.11m
ALRAlere Inc.
-1.34%43.002.9%$40.43m
DEPODepomed, Inc.
-0.57%24.2621.5%$39.31m

Company Profile

GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development and Pipeline Research & Development. The Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the Group's proprietary cannabinoid technology platform. GW Pharmaceuticals was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Salisbury, the United Kingdom.